Starting with a bioinformatics approach using publicly available databases, the authors were able to confirm that tissues from patients with lung adenocarcinoma had increased expression of BCCIP and that high expression levels of BCCIP were correlated with poor patient prognosis.
The post Study finds a possible link between BCCIP and poor patient prognosis in lung adenocarcinoma appeared first on Nexcelom Bioscience.
Nexcelom is a Massachusetts-based developer and marketer of automated cell counters, image cytometers, and related items for life science and biomedical research applications.